Supernus Pharmaceuticals, Inc. (SUPN) — Financial statements
Income statement, balance sheet, and cash flow for Supernus Pharmaceuticals, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 719↑8.6% | 662↑8.9% | 608↓8.9% | 667↑15.1% | 580 | |
| Cost of Revenue | 75↓4.3% | 78↓7.0% | 84↓3.9% | 87↑16.2% | 75 | |
| Gross Profit | 644↑10.4% | 584↑11.5% | 524↓9.7% | 580↑14.9% | 505 | |
| Operating Expenses | ||||||
| R&D Expenses | 106↓2.4% | 109↑18.8% | 92↑22.9% | 75↓17.6% | 90 | |
| General & Administrative Expenses | 197↓20.4% | 247↑4.5% | 237↑116.3% | 109↑4.2% | 105 | |
| Selling & Marketing Expenses | 289↑226.2% | 89↓11.2% | 100↓62.8% | 268↑34.1% | 200 | |
| SG&A Expenses | 486↑44.6% | 336↓0.2% | 336↓10.8% | 377↑23.8% | 305 | |
| Other Expenses | 89↑55.1% | 58↓42.9% | 101↑23.1% | 82↑250.1% | 23 | |
| Operating Expenses | 681↑35.6% | 502↓5.1% | 529↓0.9% | 534↑27.5% | 419 | |
| Total Costs & Expenses | 756↑30.3% | 580↓5.3% | 613↓1.3% | 621↑25.8% | 494 | |
| Operating Results | ||||||
| Operating Income | -37↓145.1% | 82↑1649.9% | -5↓111.4% | 46↓46.4% | 86 | |
| Depreciation & Amortization | 92↑13.9% | 80↓5.2% | 85↓0.8% | 86↑162.4% | 33 | |
| EBITDA | 43↓76.1% | 178↑98.0% | 90↓41.3% | 153↑18.7% | 129 | |
| EBIT | -49↓150.1% | 98↑1787.9% | 5↓92.4% | 68↓29.8% | 97 | |
| Interest & Other Income | ||||||
| Net Interest Income | 13↓18.2% | 16↑101.6% | 8↓45.0% | 15↑213.7% | -13 | |
| Interest Income | 13↓18.2% | 16↑55.0% | 10↓51.8% | 22↑105.2% | 11 | |
| Interest Expense | 0.00 | 0.00↓100.0% | 2↓65.8% | 7↓69.8% | 23 | |
| Non-Operating Income | 12↑175.1% | -16↓55.0% | -10↑51.8% | -22↓105.2% | -11 | |
| Other Income / Expenses | -12↓175.1% | 16↑101.6% | 8↓45.0% | 15↑213.7% | -13 | |
| Income Before Tax | -49↓150.1% | 98↑3434.5% | 3↓95.4% | 61↓17.0% | 73 | |
| Income Tax Expense | -10↓143.7% | 24↑1552.1% | 1↑4440.6% | 0.03↓99.8% | 20 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -39↓152.2% | 74↑5512.8% | 1↓97.8% | 61↑13.6% | 53 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -39↓152.2% | 74↑5512.8% | 1↓97.8% | 61↑13.6% | 53 | |
| Bottom-Line Net Income | -39↓152.2% | 74↑5512.8% | 1↓98.0% | 64↑20.3% | 53 | |
| EPS (Basic) | -0.68↓150.7% | 1.34↑5460.2% | 0.02↓97.9% | 1.13↑11.9% | 1.01 | |
| EPS (Diluted) | -0.68↓151.5% | 1.32↑5469.6% | 0.02↓97.7% | 1.04↑6.1% | 0.98 | |
| Weighted Average Shares | 56↑2.5% | 55↑1.0% | 55↑1.6% | 54↑1.1% | 53 | |
| Weighted Average Diluted Shares | 56↑0.9% | 56↑0.8% | 56↓10.0% | 62↑13.5% | 54 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.